GeminIQ Website Logo

Viewing AVLN free

Subscribe for full history, 90+ metrics, screener, watchlist...

Avalyn Pharma Inc.

AVLN

Subscribe to unlock 17+ years of data

Financial Statements

Values in Millions ($)
2026-06-30
2026-03-31
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Financial statements beyond 3 years are for subscribers only.

Unlock 17+ years of income statements, balance sheets, and cash flow statements

Start 7-day free trial
Subscriber-only column
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value
26492
Marketable Securities Current
8831
Prepaid Expense And Other Assets Current
67
Assets Current
358130
Assets Noncurrent
Property Plant And Equipment Net
11
Operating Lease Right Of Use Asset
21
Other Assets Noncurrent
33
Assets Noncurrent
676
Assets
425136
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current
33
Accrued Liabilities Current
78
Operating Lease Liability Current
11
Liabilities Current
1112
Liabilities Noncurrent
Long Term Debt Noncurrent
1515
Operating Lease Liability Noncurrent
11
Liabilities
2728
Temporary Equity
Stockholders Equity
Common Stock Value
00
Additional Paid In Capital Common Stock
72028
Accumulated Other Comprehensive Income Loss Net Of…
-00
Retained Earnings Accumulated Deficit
-321-292
Stockholders Equity
398-264
Liabilities And Stockholders Equity
425136
Series C Preferred Stock
-0
Preferred Stock Liquidation Preference Value
-373
Common Stock Par Or Stated Value Per Share
0.0010.001
Common Stock Shares Authorized
700585
Common Stock Shares Issued
441
Shares Outstanding
441

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q2 1 Month
Q2 2 Month
Q2 3 Month
202616.33%5.87%----

Earnings Market Reaction data beyond 3 years is for subscribers only.

Unlock the full earnings market reaction history

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics
2026-06-30
2026-03-31
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Metric history beyond 3 years is for subscribers only.

Unlock 17+ years of history across 90+ calculated metrics

Start 7-day free trial
Subscriber-only column
Liquidity Ratios
Current Ratio
33.12
11.03
Quick Ratio
32.60
10.45
Working Capital
347.18M
118.20M
Leverage & Debt
Debt to Equity
0.07
-0.10
Debt Ratio
0.06
0.20
Valuation Metrics
P/B TTM
2.45
-
Market Cap
976.10M
-
Enterprise Value
726.70M
-
Calculated Values
Net Debt
-249.40M
-77.50M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

Insider Transactions

2026-05-01Purchase
Owner: Carroll, Jill
Title: -
Shares: 277,778
Price/Share: $18.00
Value: $5,000,004.00
Shares Owned: 2,186,562
Relationship: Director
Ownership: Indirect
2026-05-01Purchase
Owner: Novo, Holdings A/S
Title: -
Shares: 555,555
Price/Share: $18.00
Value: $9,999,990.00
Shares Owned: 3,883,289
Relationship: TenPercentOwner
Ownership: Direct
2026-05-01Purchase
Owner: George, Simeon, Sr One Ca…
Title: -
Shares: 555,555
Price/Share: $18.00
Value: $9,999,990.00
Shares Owned: 2,186,562
Relationship: TenPercentOwner
Ownership: Indirect

Subscribe to unlock 17+ years of data

No institutional ownership data available.

Avalyn Pharma Inc. (AVLN) — SEC Financial Statements & Analysis

Avalyn Pharma Inc. (AVLN) is a pharmaceutical preparations company, incorporated in DE. Avalyn Pharma Inc. trades on Nasdaq as: AVLN. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Avalyn Pharma Inc. reported a Debt-to-Equity ratio of 0.07x, a Price-to-Book (P/B) ratio of 2.45x (TTM), at a market cap of $976.10M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity
0.07x
P/B TTM
2.45x
Market Cap
$976.10M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Avalyn Pharma Inc. in?

Avalyn Pharma Inc. (AVLN) operates in the Pharmaceutical Preparations industry.

What is AVLN's market cap?

Avalyn Pharma Inc. (AVLN) has a market capitalization of $976.10M as of 2026-06-30.

What exchange does AVLN trade on?

Avalyn Pharma Inc. (AVLN) trades on the Nasdaq.

Where is Avalyn Pharma Inc. incorporated?

Avalyn Pharma Inc. is incorporated in DE.

Wall Street's data.
Main Street's price.